Grifols (GIKLY) Land & Improvements (2020 - 2021)
Grifols (GIKLY) posted Land & Improvements of $910.2 million for Q4 2021, up 12.48% quarter-over-quarter from $809.2 million in Q4 2020, and up 12.48% year-on-year from $809.2 million in Q4 2020.
Grifols (GIKLY) Land & Improvements (2020 - 2021) Analysis & Trends
Grifols (GIKLY) has reported Land & Improvements for 2 consecutive years, with $910.2 million the latest figure, recorded in Q4 2021.
- Land & Improvements for Q4 2021 came in at $910.2 million, up 12.48% year-over-year; the trailing twelve-month figure through Dec 2021 was $910.2 million (up 12.48% YoY), and the FY2021 annual result was $910.2 million, up 17.46% from the prior year.
- Land & Improvements was $910.2 million for Q4 2021 at Grifols, up from $809.2 million in the prior quarter.
- Over five years, Land & Improvements peaked at $910.2 million in Q4 2021 and troughed at $809.2 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 910.21 Mn |
| Dec 31, 2020 | 809.20 Mn |